S1326
SB−3CT
≥98% (HPLC), matrix metalloproteinase MMP-2 and MMP-9 inhibitor, powder
Synonyme(s) :
2-[[(4-phenoxyphenyl)sulfonyl]methyl]-Thiirane
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C15H14O3S2
Numéro CAS:
Poids moléculaire :
306.40
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderNom du produit
SB−3CT, ≥98% (HPLC), powder
Quality Level
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to off-white
solubility
DMSO: >20 mg/mL
storage temp.
−20°C
SMILES string
O=S(=O)(CC1CS1)c2ccc(Oc3ccccc3)cc2
InChI
1S/C15H14O3S2/c16-20(17,11-14-10-19-14)15-8-6-13(7-9-15)18-12-4-2-1-3-5-12/h1-9,14H,10-11H2
InChI key
LSONWRHLFZYHIN-UHFFFAOYSA-N
Application
SB−3CT has been used as irreversible inhibitor of matrix metallopeptidase 9 (MMP9) in cell cultures to exclude reciprocal regulation.
Biochem/physiol Actions
SB−3CT is a potent matrix metalloproteinase MMP-2 and MMP-9 inhibitor.
SB-3CT is a potent matrix metalloproteinase MMP-2 and MMP-9 inhibitor. Matrix metalloproteinases (MMPs) are involved in a number of activities including angiogenesis and embryogenesis. In particular, gelatinases A (MMP-2) and B (MMP-9), are thought to facilitate tumor metastasis. SB-3CT exhibits a covalent mechanism based behavior in inhibition of MMP-2 and MMP-9. This inhibitor appears to have similarity to TIMP-1 and TIMP-2 in the slow-binding component of inhibition. SB-3CT has been shown to directly bind to the zinc in the catalytic site of MMP-2. SB-3CT does not affect the activities of MMP-1 (Ki = 206 μM) MMP-3 (Ki = 15 μM), or MMP-7 (Ki = 96 μM).
Legal Information
Sold under license of U.S. Patent 6,703,415.
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Chiara Sassoli et al.
Stem cells international, 2018, 5034679-5034679 (2018-05-02)
Bone marrow-derived mesenchymal stromal cell- (BM-MSC-) based therapy is a promising option for regenerative medicine. An important role in the control of the processes influencing the BM-MSC therapeutic efficacy, namely, extracellular matrix remodelling and proliferation and secretion ability, is played
Youqiong Ye et al.
Genome medicine, 12(1), 83-83 (2020-09-30)
Immune checkpoint blockade (ICB) therapy has demonstrated considerable clinical benefit in several malignancies, but has shown favorable response in only a small proportion of cancer patients. Recent studies have shown that matrix metalloproteinases (MMPs) are highly associated with the microenvironment
Hongxia Cai et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 25(6), 1448-1459 (2017-04-12)
Matrix metalloproteinase 9 (MMP-9) plays a beneficial role in the delayed phase of middle cerebral artery occlusion (MCAO). However, the mechanism is obscure. Here, we constructed hypoxia response element (HRE)-regulated MMP-9 to explore its effect on glial scars and neurogenesis in